Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK4 | Q13043 | 13/20 | 0.63 |
| ▸ | STK3 | Q13188 | 13/20 | 0.63 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539127 | 0.94 | STK4 (0.71) | STK4STK3LRRK2TP53JAK2 | |
| SCHEMBL3537467 | 0.82 | LRRK2 (0.67) | STK4STK3LRRK2TP53JAK2 | |
| SCHEMBL7087807 | 0.81 | STK4 (0.64) | STK4STK3LRRK2 | |
| SCHEMBL31301542 | 0.78 | STK4 (1.00) | STK4STK3LRRK2 | |
| SCHEMBL31301652 | 0.77 | LRRK2 (1.00) | STK4STK3LRRK2JAK2JAK3 | |
| SCHEMBL3542500 | 0.76 | LRRK2 (0.58) | STK4STK3LRRK2JAK2JAK1 | |
| SCHEMBL3539122 | 0.74 | STK3 (0.60) | STK4STK3LRRK2 | |
| SCHEMBL3536209 | 0.74 | JAK3 (0.56) | LRRK2TP53JAK2JAK1JAK3 | |
| SCHEMBL3536056 | 0.74 | JAK3 (0.56) | LRRK2TP53JAK2JAK1JAK3 | |
| SCHEMBL31301635 | 0.73 | STK4 (0.84) | STK4STK3LRRK2JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1087970-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065908-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | STK4 425/4885STK3 211/4885LRRK2 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.